This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays

October 18, 2023 — DeepTek.ai, a leading medical imaging AI company in India has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its revolutionary Chest X-ray AI solution - CXR Analyzer. This advanced technology uses deep learning algorithms to detect abnormalities in chest X-rays. It identifies, categorizes, and highlights suspicious areas automatically, aiding clinicians in making precise interpretations. 

Unlike traditional point AI solutions identifying a specific pathology, DeepTek's Chest X-ray AI covers the entire chest area, offering analysis for a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest. It's compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units making it versatile and powerful. 

This AI model accelerates decision-making by detecting and locating suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases. In a world with 3.5 billion annual X-rays, 1.5 billion are chest X-rays, making the need for precise interpretation essential. The shortage of radiologists further emphasizes the role of AI in addressing this challenge. 

Dr. Amit Kharat, Co-Founder of DeepTek.ai, quoted "DeepTek CXR Analyzer v1.0 is a game-changer, reducing radiologist workload by an impressive 30-50%. With FDA clearance, we're not only accessing the vast US healthcare market but also impacting lives globally. By swiftly identifying lung abnormalities and offering precise mapping, we're unlocking a world of possibilities for improved outcomes across various medical specialties." 

DeepTek's AI solutions have been transforming healthcare in India and the Asia-Pacific region by providing increased access to quality care at a lower cost. Over 500 hospitals and imaging centers are using DeepTek's AI solutions, impacting the lives of 100,000 people monthly. More than half a million people have been screened using DeepTek's Chest X-Ray Analyzer for tuberculosis screening. In Singapore, DeepTek's US FDA approved Platform - Augmento has been deployed as the National Radiology AI platform, boosting productivity and quality of care across all public hospitals. 

With its operations in Pune; DeepTek has about 200 members and has partners like TATA Capital, NTT DATA Japan and Shimadzu Asia Pacific. 

For more information, visit : www.deeptek.ai 

Find more RSNA23 related coverage here


Additional Content

News | Radiology Imaging

Nov. 2, 2026 — Neurophet and RapidAI have partnered to integrate Neurophet’s advanced neurodegenerative brain imaging ...

Time November 04, 2026
arrow
News | Ultrasound Imaging

Oct. 28, 2026 — Clarius Mobile Health has announced 30 specialized AI models are now integrated into Clarius App 13.1 ...

Time November 02, 2026
arrow
News | Lung Imaging

Nov.2, 2026 – SimonMed has announced the clinical launch of two advanced lung imaging technologies, CT:VQ and LDAf, in ...

Time November 02, 2026
arrow
News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | X-Ray

Oct. 27, 2026 — AZmed has announced that its FDA-cleared AZtrauma and AZchest X-ray AI applications are available ...

Time October 29, 2026
arrow
Subscribe Now